Maxcyte (MXCT) Receivables (2020 - 2026)

Maxcyte (MXCT) has reported Receivables for 7 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables fell 31.83% year-over-year to $3.9 million in Q2 2026; TTM through Jun 2026 was $3.9 million, a 31.83% decrease from a year earlier, with the FY2025 full-year figure at $3.5 million, down 25.18% from the prior year.
• Receivables was $3.9 million for Q2 2026 at Maxcyte, down from $4.2 million in the prior quarter.
• Over five years, Receivables peaked at $11.2 million in Q4 2022 and troughed at $3.5 million in Q4 2025.
• A 5-year average of $6.4 million and a median of $5.9 million in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables slumped 48.3% in 2023 and surged 82.15% in 2025, its largest moves.
• Over 5 years, Receivables stood at $11.2 million in 2022, then sank by 48.3% to $5.8 million in 2023, then dropped by 18.97% to $4.7 million in 2024, then dropped by 25.18% to $3.5 million in 2025, then increased by 11.96% to $3.9 million in 2026.
• The last three Receivables figures came in at $3.9 million (Q2 2026), $4.2 million (Q1 2026), and $3.5 million (Q4 2025), per Business Quant data.